Tags : Licensing Agreement

Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin

Shots: Chugai and Sanofi terminate their 2012 licensing agreement, allowing Sanofi to transfer marketing rights of Apleway to Kowa as of Apr 01, 2020 with the anticipated transfer of marketing authorization in Jun’2020 In 2012, Chugai granted Kowa & Sanofi commercial rights of tofogliflozin 20mg under the brand name Deberza & Apleway respectively, following the […]Read More

Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

Shots: Under the expanded collaboration, Equillium gets an exclusive right to develop and commercialize Biocon’s itolizumab in Australia and New Zealand. In May’2017, Biocon partnered with Equillium to develop a therapy for autoimmune disorders under which Equillium has granted an exclusive right for the therapy in the US and Canada The expansion will allow Equillium […]Read More

Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to

Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 in combination with its KRAS inhibitors for patients with gastrointestinal and lung cancers harboring KRAS mutations The focus of the agreement is to robust Boehringer’s […]Read More